IMPORTANCE: Epileptic activity associated with Alzheimer disease (AD) deserves increased attention because it has a harmful impact on these patients, can easily go unrecognized and untreated, and may reflect pathogenic processes that also contribute to other aspects of the illness. We report key features of AD-related seizures and epileptiform activity that are instructive for clinical practice and highlight similarities between AD and transgenic animal models of the disease. OBJECTIVE: To describe common clinical characteristics and treatment outcomes of patients with amnestic mild cognitive impairment (aMCI) or early AD who also have epilepsy or subclinical epileptiform activity. DESIGN: Retrospective observational study from 2007 to 2012. SETTING Memory and Aging Center, University of California, San Francisco. PATIENTS: We studied 54 patients with a diagnosis of aMCI plus epilepsy (n = 12), AD plus epilepsy (n = 35), and AD plus subclinical epileptiform activity (n = 7). MAIN OUTCOMES AND MEASURES: Clinical and demographic data, electroencephalogram (EEG) readings, and treatment responses to antiepileptic medications. RESULTS: Patients with aMCI who had epilepsy presented with symptoms of cognitive decline 6.8 years earlier than patients with aMCI who did not have epilepsy (64.3 vs 71.1 years; P = .02). Patients with AD who had epilepsy presented with cognitive decline 5.5 years earlier than patients with AD who did not have epilepsy (64.8 vs 70.3 years; P = .001). Patients with AD who had subclinical epileptiform activity also had an early onset of cognitive decline (58.9 years). The timing of seizure onset in patients with aMCI and AD was nonuniform (P < .001), clustering near the onset of cognitive decline. Epilepsies were most often complex partial seizures (47%) and more than half were nonconvulsive (55%). Serial or extended EEG monitoring appeared to be more effective than routine EEG at detecting interictal and subclinical epileptiform activity. Epileptic foci were predominantly unilateral and temporal. Of the most commonly prescribed antiepileptics, treatment outcomes appeared to be better for lamotrigine and levetiracetam than for phenytoin. CONCLUSIONS AND RELEVANCE: Common clinical features of patients with aMCI- or AD-associated epilepsy at our center included early age at onset of cognitive decline, early incidence of seizures in the disease course, unilateral temporal epileptic foci detected by serial/extended EEG, transient cognitive dysfunction, and good seizure control and tolerability with lamotrigine and levetiracetam. Careful identification and treatment of epilepsy in such patients may improve their clinical course.
IMPORTANCE: Epileptic activity associated with Alzheimer disease (AD) deserves increased attention because it has a harmful impact on these patients, can easily go unrecognized and untreated, and may reflect pathogenic processes that also contribute to other aspects of the illness. We report key features of AD-related seizures and epileptiform activity that are instructive for clinical practice and highlight similarities between AD and transgenic animal models of the disease. OBJECTIVE: To describe common clinical characteristics and treatment outcomes of patients with amnestic mild cognitive impairment (aMCI) or early AD who also have epilepsy or subclinical epileptiform activity. DESIGN: Retrospective observational study from 2007 to 2012. SETTING Memory and Aging Center, University of California, San Francisco. PATIENTS: We studied 54 patients with a diagnosis of aMCI plus epilepsy (n = 12), AD plus epilepsy (n = 35), and AD plus subclinical epileptiform activity (n = 7). MAIN OUTCOMES AND MEASURES: Clinical and demographic data, electroencephalogram (EEG) readings, and treatment responses to antiepileptic medications. RESULTS:Patients with aMCI who had epilepsy presented with symptoms of cognitive decline 6.8 years earlier than patients with aMCI who did not have epilepsy (64.3 vs 71.1 years; P = .02). Patients with AD who had epilepsy presented with cognitive decline 5.5 years earlier than patients with AD who did not have epilepsy (64.8 vs 70.3 years; P = .001). Patients with AD who had subclinical epileptiform activity also had an early onset of cognitive decline (58.9 years). The timing of seizure onset in patients with aMCI and AD was nonuniform (P < .001), clustering near the onset of cognitive decline. Epilepsies were most often complex partial seizures (47%) and more than half were nonconvulsive (55%). Serial or extended EEG monitoring appeared to be more effective than routine EEG at detecting interictal and subclinical epileptiform activity. Epileptic foci were predominantly unilateral and temporal. Of the most commonly prescribed antiepileptics, treatment outcomes appeared to be better for lamotrigine and levetiracetam than for phenytoin. CONCLUSIONS AND RELEVANCE: Common clinical features of patients with aMCI- or AD-associated epilepsy at our center included early age at onset of cognitive decline, early incidence of seizures in the disease course, unilateral temporal epileptic foci detected by serial/extended EEG, transient cognitive dysfunction, and good seizure control and tolerability with lamotrigine and levetiracetam. Careful identification and treatment of epilepsy in such patients may improve their clinical course.
Authors: Maarten Liedorp; Cornelis J Stam; Wiesje M van der Flier; Yolande A L Pijnenburg; Philip Scheltens Journal: Dement Geriatr Cogn Disord Date: 2010-05-26 Impact factor: 2.959
Authors: E D Roberson; J H Hesse; K D Rose; H Slama; J K Johnson; K Yaffe; M S Forman; C A Miller; J Q Trojanowski; J H Kramer; B L Miller Journal: Neurology Date: 2005-09-13 Impact factor: 9.910
Authors: Robert S Fisher; Walter van Emde Boas; Warren Blume; Christian Elger; Pierre Genton; Phillip Lee; Jerome Engel Journal: Epilepsia Date: 2005-04 Impact factor: 5.864
Authors: Laure Verret; Edward O Mann; Giao B Hang; Albert M I Barth; Inma Cobos; Kaitlyn Ho; Nino Devidze; Eliezer Masliah; Anatol C Kreitzer; Istvan Mody; Lennart Mucke; Jorge J Palop Journal: Cell Date: 2012-04-27 Impact factor: 41.582
Authors: B L Plassman; R J Havlik; D C Steffens; M J Helms; T N Newman; D Drosdick; C Phillips; B A Gau; K A Welsh-Bohmer; J R Burke; J M Guralnik; J C Breitner Journal: Neurology Date: 2000-10-24 Impact factor: 9.910
Authors: Jorge J Palop; Jeannie Chin; Erik D Roberson; Jun Wang; Myo T Thwin; Nga Bien-Ly; Jong Yoo; Kaitlyn O Ho; Gui-Qiu Yu; Anatol Kreitzer; Steven Finkbeiner; Jeffrey L Noebels; Lennart Mucke Journal: Neuron Date: 2007-09-06 Impact factor: 17.173
Authors: Alicia M Hall; Benjamin T Throesch; Susan C Buckingham; Sean J Markwardt; Yin Peng; Qin Wang; Dax A Hoffman; Erik D Roberson Journal: J Neurosci Date: 2015-04-15 Impact factor: 6.167
Authors: Michael E Ward; Robert Chen; Hsin-Yi Huang; Connor Ludwig; Maria Telpoukhovskaia; Ali Taubes; Helene Boudin; Sakura S Minami; Meredith Reichert; Philipp Albrecht; Jeffrey M Gelfand; Andres Cruz-Herranz; Christian Cordano; Marcel V Alavi; Shannon Leslie; William W Seeley; Bruce L Miller; Eileen Bigio; Marek-Marsel Mesulam; Matthew S Bogyo; Ian R Mackenzie; John F Staropoli; Susan L Cotman; Eric J Huang; Li Gan; Ari J Green Journal: Sci Transl Med Date: 2017-04-12 Impact factor: 17.956
Authors: Magdalena Martinez-Losa; Tara E Tracy; Keran Ma; Laure Verret; Alexandra Clemente-Perez; Abdullah S Khan; Inma Cobos; Kaitlyn Ho; Li Gan; Lennart Mucke; Manuel Alvarez-Dolado; Jorge J Palop Journal: Neuron Date: 2018-03-15 Impact factor: 17.173
Authors: Keith A Vossel; Kamalini G Ranasinghe; Alexander J Beagle; Danielle Mizuiri; Susanne M Honma; Anne F Dowling; Sonja M Darwish; Victoria Van Berlo; Deborah E Barnes; Mary Mantle; Anna M Karydas; Giovanni Coppola; Erik D Roberson; Bruce L Miller; Paul A Garcia; Heidi E Kirsch; Lennart Mucke; Srikantan S Nagarajan Journal: Ann Neurol Date: 2016-11-07 Impact factor: 10.422
Authors: Willem Huijbers; Aaron P Schultz; Kathryn V Papp; Molly R LaPoint; Bernard Hanseeuw; Jasmeer P Chhatwal; Trey Hedden; Keith A Johnson; Reisa A Sperling Journal: J Neurosci Date: 2018-11-27 Impact factor: 6.167
Authors: Peter Dongmin Sohn; Cindy Tzu-Ling Huang; Rui Yan; Li Fan; Tara E Tracy; Carolina M Camargo; Kelly M Montgomery; Taylor Arhar; Sue-Ann Mok; Rebecca Freilich; Justin Baik; Manni He; Shiaoching Gong; Erik D Roberson; Celeste M Karch; Jason E Gestwicki; Ke Xu; Kenneth S Kosik; Li Gan Journal: Neuron Date: 2019-09-18 Impact factor: 17.173
Authors: Rani A Sarkis; Louis Beers; Emile Farah; Mohammad Al-Akaidi; Yuxiang Zhang; Joseph J Locascio; Michael J Properzi; Aaron P Schultz; Jasmeer P Chhatwal; Keith A Johnson; Reisa A Sperling; Page B Pennell; Gad A Marshall Journal: Clin Neurophysiol Date: 2020-09-19 Impact factor: 3.708